Target intelligence / Profile preview

Transcription initiation factor TFIID subunit 5 (TAF5)

Target
TAF5
Molecular classification
Transcription factor, General transcription factor complex subunit, TBP-associated factor
01

Overview

Transcription initiation factor TFIID subunit 5 (TAF5) is a core component of the TFIID complex, which is essential for the initiation of transcription by RNA polymerase II[1][6]. TFIID includes the TATA-box-binding protein (TBP) and multiple TBP-associated factors (TAFs), with TAF5 acting as a structural and functional subunit involved in the formation of nucleosome-like structures within TFIID[1][2]. TAF5 mediates protein–protein interactions within the TFIID complex, contributes to promoter recognition, and is involved in the assembly of the pre-initiation complex necessary for accurate transcription initiation[1][2][6]. The TFIID complex, with TAF5, functions broadly in gene expression and is implicated in the cellular response to various activators and repressors[2]. While genetic variations in TAF5 have been associated with certain cancers such as prostate adenocarcinoma and medulloblastoma, TAF5 itself is not a typical drug target and there are no known therapeutic agents that selectively modulate its activity[1].

Other names
TAF2DTAF(II)100TAFII-100TAFII100Transcription initiation factor TFIID 100 kDa subunitTAF5 RNA polymerase IITATA box binding protein (TBP)-associated factor 100kDaTATA box binding protein (TBP)-associated factor 2DTATA box binding protein (TBP)-associated factor, RNA polymerase II, D, 100kD
02

Biological functions

Regulation of transcription initiation by RNA polymerase IIPromoter recognitionAssembly of the transcription pre-initiation complexModulation of transcriptional responses to regulatory signals
03

Disease associations

Cancer (notably prostate adenocarcinoma and medulloblastoma)Other (there is no direct evidence supporting a primary causal role in disease, but genetic variations may be linked to cancer susceptibility)
04

Safety considerations

Targeting TAF5 directly would risk disrupting global transcription, presenting a broad risk of cytotoxicity or unmanageable systemic effectsNo known targeted drugs or clinical interventions exist for TAF5

Beyond the preview

Go deeper on Transcription initiation factor TFIID subunit 5 (TAF5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcription initiation factor TFIID subunit 5 (TAF5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call